期刊文献+

肾癌生物治疗的研究进展 被引量:1

Advance in biotherapy for renal cell carcinoma
下载PDF
导出
摘要 肾细胞癌是泌尿系统肿瘤中常见的恶性肿瘤,近几年发病率呈增长的趋势。由于该肿瘤对放、化疗及内分泌治疗效果均不理想,目前仍然以传统手术治疗为主。伴随分子生物学、免疫学、基因工程技术的迅速发展,肾细胞癌也以其特殊的生物学特性使其在细胞因子类药物治疗、肾癌疫苗治疗以及分子靶向治疗等生物免疫治疗方面显示出良好的应用前景。 Renal cell carcinoma (RCC) is one of the most frequent urologic malignancies and its incidence is in-creasing in these years. Because conventional radiotherapy,chemotherapy and endocrine therapy are ineffective for the majority of RCC,surgical therapy is still the main treatment at present. Along with the development of molecular biology,immunology and gene engineering,immunotherapeutic treatments for RCC,including gene,dendritic cell,vaccine represent a bright prospect. This paper overviews the advancement in biotherapy of renal cell carcinoma in recent years.
出处 《中国医学工程》 2008年第4期279-282,共4页 China Medical Engineering
关键词 肾肿瘤 生物治疗 kidney carcinoma biotherapy
  • 相关文献

参考文献26

  • 1Cor H. J. Lamers,Sabine C. L. Langeveld,Corrien M. Groot-van Ruijven,Reno Debets,Stefan Sleijfer,Jan Willem Gratama.Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo[J]Cancer Immunology Immunotherapy,2007(12).
  • 2Jose Alexandre M. Barbuto,Luis F. C. Ensina,Andreia R. Neves,Patrícia C. Bergami-Santos,Katia R. M. Leite,Ricardo Marques,Frederico Costa,Siderleny C. Martins,Luiz H. Camara-Lopes,Antonio C. Buzaid.Dendritic cell–tumor cell hybrid vaccination for metastatic cancer[J]Cancer Immunology Immunotherapy,2004(12).
  • 3HUDES GR,CARDUCCI M,TOMCZAK P,et al.A phase3,random-ized,3-arm study of temsirolimus(TEMSR)or interferon-alpha(IFN)or the combination of TEMSR+IFN in the treatment of first-line,poor-risk patients with advanced renal cell carcinoma(adv RCC)Journal of Clinical Oncology,2006.
  • 4LAMERS CH,LANGEVELD SC,GROOT-VAN RUIJYEN CM,et al.Gene-modified T cells for adoptive immunotherapy of renal cell can-cer maintain transgene-specific immune functions in vivoCancer ImmunologyImmunotherapy:CII,2007.
  • 5DAVIS ID.A pilot study of monoclonal antibody cG250and low dose subcutaneous IL-2in patients with advanced renal cell carcinomaA Journal of the Academy of Cancer Immunology,2007.
  • 6DAVIS ID.A phase I multiple dose,dose escalation study of cG250monoclonal antibody in patients with advanced renal cell carcinomaA Journal of the Academy of Cancer Immunology,2007.
  • 7Jemal A,Murray T,Ward E,et al.Cancer statistics, 2005CA a Cancer Journal for Clinicians,2005.
  • 8Holtl L,Rieser C,Papesh C,et al.Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cellsJournal of Urology The,1999.
  • 9Motzer RJ,Michaelson MD,Redman BG,et al.Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinomaJournal of Clinical Oncology,2006.
  • 10Janzen NK;Kim HL;Figlin RA.Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease,2003(04).

共引文献2

同被引文献16

  • 1张亚东,李晓飞.肾癌G250MN/CAIX抗原的研究进展[J].国外医学(泌尿系统分册),2005,25(1):12-16. 被引量:3
  • 2任淑萍,包木胜,高新,于永利,王丽颖.HSP65-MUC1/HSP65抗体免疫复合物对人树突状细胞的活化作用[J].吉林大学学报(医学版),2005,31(2):182-185. 被引量:6
  • 3Krutzik SR,Tan B,Li H,et al.TLR activation triggers the rapiddifferentiation of monocytes into macrophages and dendritic cells[J].Nat Med,2005,11(6):653-660.
  • 4Reinhard G,Marten A,Kiske SM,et al.Generation of dendriticcell-based vaccines for cancer therapy[J].Br J Cancer,2002,86(10):1529-1533.
  • 5Akiyama K,Ebihara S,Yada A,et al.Targeting apoptotic tumorcells to FcγR provides efficient and versatile vaccination againsttumors by dendritic cells[J].J Immunol,2003,170(4):1641-1648.
  • 6Dubois B,Lamy PJ,Chemin K,et al.Measles virus exploits den-dritic cells to suppress CD4+T-cell proliferation via expression ofsurface viral lycoproteins independently of T-cell trans-infection[J].Cell Immunol,2001,214(2):173-183.
  • 7Mehta RC,Pike GB,Enzmann DR.Magnetization transfer MR ofin cancer development and progression[J].Int J Biol Markers,1998,13(2):51-69.
  • 8Pan CC,Chen PC,Tsay SH,et al.Differential immunoprofiles ofhepatocellular carcinoma,renal cell carcinoma,and adrenocoryicalcarcinoma:A systemic immunohistochemical survey using tissuearray technique[J].Appl Immunohistochem Mol Morphol,2005,13(4):347-352.
  • 9Yamagata M,Hasuda K,Stamato T,et al.The contribution of lac-tic acid to acidification of tumours:Studies of variant cells lackinglactate dehydrogenase[J].British J Cancer,1998,77(11):1726-1731.
  • 10Tso CL,Zisman A,Pantuck A,et al.Induction of G250-targetedand T-cell-mediated antitumor activity against renal cell carcinomausing a chimeric fusion protein consisting of G250 and granulocyte/monocyte-conlony stimulating factor[J].Cancer Res,2001,61(21):7925-7933.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部